JF
OVID icon

Jump Financial’s Ovid Therapeutics OVID Stock Holding History

Jump Financial’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,718
Closed -$4.53K – 2091
2025
Q2 		$4.53K Buy
+13,718
New +$4.13K ﹤0.01% 1740
2023
Q4 		– Sell
-15,811
Closed -$60.7K – 2112
2023
Q3 		$60.7K Buy
+15,811
New +$56.8K ﹤0.01% 1732
2022
Q1 		– Sell
-16,600
Closed -$53K – 1808
2021
Q4 		$53K Buy
+16,600
New +$56.9K ﹤0.01% 1304
2021
Q3 		– Sell
-16,200
Closed -$63K – 1393
2021
Q2 		$63K Buy
+16,200
New +$63.9K 0.01% 1019
2020
Q4 		– Sell
-12,300
Closed -$70K – 1118
2020
Q3 		$70K Buy
+12,300
New +$82.3K 0.01% 713

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Jump Financial's OVID Position: Q3 2025 in Review

Jump Financial sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 13,718 shares — an estimated $4.53K sold.

Jump Financial first reported a position in OVID in Q3 2020 and held it in 5 quarters. The position peaked at $70K in Q3 2020. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • Jump Financial reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jump Financial sold 13,718 Ovid Therapeutics shares in Q3 2025, an estimated $4.53K.
  • Jump Financial first reported a position in Ovid Therapeutics in Q3 2020 and held it in 5 quarters.
  • Jump Financial's Ovid Therapeutics position peaked at $70K in Q3 2020.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.